touchPODCAST

Clinical updates from SGO 2023 on PARP inhibitors in ovarian cancer

touchCONGRESS for touchONCOLOGY

Listen to renowned experts in gynaecological oncology Dr Domenica Lorusso, Dr Susana Banerjee and Prof. Frederik Marmé review key data presented at SGO 2023 on recent developments in the use of PARP inhibitors in ovarian cancer. Aspects covered include first-line maintenance therapy, selection and sequencing implications, and future directions including emerging neoadjuvant and combination regimens. They also discuss how these latest data may impact clinical practice.

Clinical themes:

1. Update on first-line PARP inhibitor maintenance in ovarian cancer: Where are we now? (02:31)
2. Selection and sequencing implications for PARP inhibitors in ovarian cancer emerging from the latest data: What should we consider, and when? (19:51)
3. Emerging PARP inhibitor-based neoadjuvant and combination regimens in ovarian cancer: Where are we heading? (40:10)

The internationally renowned expert faculty: 

• Dr Domenica Lorusso, Fondazione Policlinico Universitario A Gemelli, Rome, Italy
• Dr Susana Banerjee, The Royal Marsden NHS Foundation Trust, London, UK
• Prof. Frederik Marmé, University Hospital Heidelberg, Heidelberg, Germany

This touchPODCAST is for HCPs outside of the USA only.

This activity is funded by an independent medical education grant from GlaxoSmithKline, and is provided by touchIME.

For further information visit our website: https://touchoncology.com/education/congress-sgo-2023-updates-parp-inhibitors-ovarian-cancer/

 

Improving outcomes in pulmonary arterial hypertension: A multidisciplinary approach

touchEXPERT OPINIONS for touchRESPIRATORY

Listen to three experts as they share their perspectives and best-practice guidance on how to optimize the diagnosis and management of pulmonary arterial hypertension.

The experts:

• Prof. Harrison Farber, Tufts Medical Center, Boston, MA, USA
• Prof. Marion Delcroix, University Hospitals Leuven, Belgium
• Prof. Stephan Rosenkranz, University of Cologne, Germany

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Merck & Co. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchrespiratoryime.org/improving-outcomes-in-pulmonary-arterial-hypertension-a-multidisciplinary-approach/

Improving outcomes in pulmonary arterial hypertension: A multidisciplinary approach

touchEXPERT OPINIONS for touchCARDIO

Listen to three experts as they share their perspectives and best-practice guidance on how to optimize the diagnosis and management of pulmonary arterial hypertension.

The experts:

• Prof. Harrison Farber, Tufts Medical Center, Boston, MA, USA
• Prof. Marion Delcroix, University Hospitals Leuven, Belgium
• Prof. Stephan Rosenkranz, University of Cologne, Germany

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Merck & Co. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchcardioime.org/improving-outcomes-in-pulmonary-arterial-hypertension-a-multidisciplinary-approach/

ICI-based combinations for advanced/metastatic renal cell carcinoma: Highlights from ASCO GU 2023

touchCONGRESS for touchONCOLOGY

Listen to renowned renal cell carcinoma (RCC) expert Prof. Brian Rini review key data presented at the ASCO GU 2023 congress on advances in immune checkpoint inhibitor (ICI)-based regimens for RCC. He also discusses with two additional leading RCC experts, Prof. Elizabeth Plimack and Prof. Thomas Powles, how these data may apply in clinical practice.

Overview:

• Data reviews with Prof. Brian Rini
• Expert panel discussions with Prof. Brian Rini, Prof. Elizabeth Plimack and Prof. Thomas Powles on the themes below

Clinical themes:

1. ICI-based combinations in the treatment of advanced/metastatic RCC: What do the latest efficacy and safety data show?
2. What is the potential role of biomarkers in predicting response to ICI-based combinations in patients with advanced/metastatic RCC?
3. How might the latest data for ICI-based combinations for advanced/metastatic RCC be implemented in clinical practice?

The internationally renowned RCC expert faculty:

• Prof. Brian Rini, Vanderbilt University Medical Center, Nashville, TN, USA
• Prof. Elizabeth Plimack, Fox Chase Cancer Center, Philadelphia, PA, USA
• Prof. Thomas Powles, Barts Cancer Centre, St Bartholomew’s Hospital, London, UK

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Merck & Co. Inc. and Exelixis Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/congress-renal-cell-carcinoma-asco-gu-2023/

Blood-based biomarkers: Supporting the diagnosis and treatment of Alzheimer’s disease

touchSATELLITE SYMPOSIUM for touchNEUROLOGY

Listen to this touch satellite symposium recorded live in March 2023 at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders.

Prof. Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA), the chair for the symposium, is joined by Prof. Liana Apostolova (Indiana University School of Medicine, Indianapolis, IN, USA), Prof. Oskar Hansson (Lund University, Lund, Sweden) and Prof. Charlotte Teunissen (Amsterdam University Medical Centers, Amsterdam, The Netherlands). 

The first session, led by Prof. Liana Apostolova (05:44), focuses on the importance of a timely and accurate diagnosis based on the underlying pathophysiology of Alzheimer’s disease (AD) and how this informs the ATN classification system for AD biomarkers. This is followed by audience Q&A (18:30).

The second session, led by Prof. Oskar Hansson (33:09), discusses the validity and performance data for AD blood-based biomarkers in comparison to current neuroimaging. This is followed by audience Q&A (49:12).

In the third session, Prof. Charlotte Teunissen (01:01:05) looks at how blood-based biomarkers may revolutionize the diagnostic and prognostic work-up of AD and improve the design of interventional trials, with the potential to be easily accessible for widespread clinical use. This is followed by audience Q&A (01:18:48). 

The symposium concludes with a panel discussion in which the faculty provide their insights on selected Q&A from the audience (01:29:40).

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Eli Lilly and Company. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchneurologyime.org/blood-based-biomarkers-diagnosis-treatment-alzheimers-disease/

Reducing transmission of COVID-19 Spotlight on vaccines

touchPANEL DISCUSSION for touchINFECTIOUS DISEASES

Listen to a panel of regional experts discuss the current landscape of COVID-19 vaccination, possible barriers to vaccine uptake and strategies involving healthcare workers that may help to improve acceptance of the COVID-19 vaccine, with a focus on Africa and the Middle East.

The experts:

• Dr Angus Thomson, IRIMI company, Lyon, France
• Dr Amaya Gillespie, WHO/UNICEF, Jordan
• Dr Henry Kyobe Bosa, Ministry of Health, Uganda

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Moderna, Inc. This activity is jointly provided by USF Health and touchIME. 

For further information please visit: www.touchinfectiousdiseasesime.org/spotlight-on-covid-19-vaccines/

Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer: Current status and future perspectives

touchEXPERT OPINIONS for touchONCOLOGY

Listen to three experts provide their insights on unmet needs, emerging therapies, and the importance of biomarker testing in HER2-negative gastric cancer/gastroesophageal junction cancer.

The experts:

• Dr Reetu Mukherji, MedStar Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA
• Dr Jaffer Ajani, Houston, TX, USA
• Dr Nataliya Uboha, University of Wisconsin, Madison, WI, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Astellas Pharma Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/exp_opin_HER2_negative_gastric_or_GE_junction_cancer 

Optimizing strategies for the treatment of colorectal cancer in the biomarker era - Modules 1 & 2

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of leading experts discuss the role of biomarkers in optimizing the treatment of colorectal cancer, and how biomarkers are shaping the evolving treatment landscape.

 The experts:

• Dr Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan
• Dr Chiara Cremolini, University of Pisa, Pisa, Italy
• Dr Rachel Riechelmann, AC Camargo Cancer Center, São Paulo, Brazil

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from the Healthcare Business of Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME.

For further information please visit: https://touchoncologyime.org/pd-treatment-of-crc-in-the-biomarker-era/

Improving outcomes of immune-related adverse events: The crucial role of the pharmacist

touchPANEL DISCUSSION for touchONCOLOGY

Listen to a panel of three oncology pharmacists discuss how to improve outcomes for patients experiencing immune-related adverse events after receiving immunotherapy for cancer treatment. 

The experts; 

• Dr Sandra Cuellar, University of Illinois, Chicago, IL, USA; 
• Dr Sonia Amin Thomas, Wellstar North Fulton Hospital and Northwest Georgia Oncology Center, Roswell, GA, USA; 
• Ms Meera Desai, University College London Hospitals NHS Foundation Trust, London, UK; 

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from MSD and is jointly provided by USF Health and touchIME. 

For further information visit: https://touchoncologyime.org/pharmacist-role-iraes/ 

Optimizing patient outcomes in Cushing’s disease

touchMDT for touchENDOCRINOLOGY

An endocrinologist, a pituitary surgeon, a pituitary nurse specialist and a patient with Cushing's disease in remission share their views on how the multidisciplinary team can support patients with Cushing’s disease.

The multidisciplinary team

• Pituitary surgeon: Dr Timothy Smith, Boston, MA, USA
• Endocrinologist: Dr Laurence Katznelson, Stanford, CA, USA
• Pituitary nurse specialist: Mrs Sandra Ramsburg, Baltimore, MD, USA
• Patient in remission/patient advocate: Ms Sharmyn McGraw, Orange County, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Recordati Rare Diseases and Xeris Pharmaceuticals, Inc., and is jointly provided by USF Health and touchIME.

For further information visit our website: touchENDOCRINOLOGY